Purpose

The management of advanced classical Hodgkin lymphoma (cHL) poses a major challenge in Asia, given disparities in health care resources and the variability in health care systems across the region. This article reviews the practice landscape for advanced cHL in East and Southeast Asia (hereafter referred to as Asia), offers detailed perspectives on the challenges faced by treating physicians, and proposes solutions to improve patient outcomes.

Methods

At the Singapore Lymphoma Scientific Symposium 2024, a panel of lymphoma experts from 10 countries/territories across Asia convened to discuss local cHL management practices. Discussions were supplemented by perspectives from an expert from the United States and a review of published literature on HL in Asia in 2014-2024. This article summarizes meeting discussions and reports relevant aspects of Asian practice preferences for advanced cHL.

Results

In Asia, cHL management is hindered by the lack of local guidelines and survivorship programs, challenges in diagnosis and staging because of a lack of resources and funding, and limited access to efficacious novel drugs. This is of particular concern in vulnerable patient populations such as the elderly. To uplift the standard of care for patients with cHL locally, greater cross-regional learning and collaboration could be explored to enhance clinical management capabilities, lower the financial barriers to accessing novel drugs and technologies, and support increased research efforts and clinical trial presence in the region.

Conclusion

Although advanced cHL management remains a challenge in Asia because of diverse needs within the region, regional partnerships and initiatives can bridge existing gaps and supplement local efforts to improve outcomes among patients with advanced cHL.

1. Alaggio, R., Amador, C., Anagnostopoulos, I., Attygalle, A. D., Araujo, I. B. O., Berti, E., Bhagat, G., Borges, A. M., Boyer, D., Calaminici, M., Chadburn, A., Chan, J. K. C., Cheuk, W., Chng, W.-J., Choi, J. K., Chuang, S.-S., Coupland, S. E., Czader, M., Dave, S. S., ... de Jong, D. (2022). The 5th edition of the World Health Organization classification of haematolymphoid tumours: Lymphoid neoplasms. Leukemia, 36(7), 1720–1748. https://doi.org/10.1038/s41375-022-01620-2
2. Reid, J. H., Marini, B. L., Nachar, V. R., Brown, A. C., & Devata, S. (2020). Contemporary treatment options for a classical disease: Advanced Hodgkin lymphoma. Critical Reviews in Oncology/Hematology, 148, Article 102897. https://doi.org/10.1016/j.critrevonc.2020.102897
3. Brice, P., de Kerviler, E., & Friedberg, J. W. (2021). Classical Hodgkin lymphoma. The Lancet, 398(10309), 1518–1527. https://doi.org/10.1016/S0140-6736(21)00156-2
4. Connors, J. M., Cozen, W., Steidl, C., Carbone, A., Hoppe, R. T., Flechtner, H.-H., & Bartlett, N. L. (2020). Hodgkin lymphoma. Nature Reviews Disease Primers, 6, Article 61. https://doi.org/10.1038/s41572-020-0189-6
5. Cheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., Lister, T. A., Armitage, J. O., Castellino, S. M., Colombat, P., Hodge, P., Horning, S. J., Kahl, B. S., Marcus, R., Martelli, M., Pfreundschuh, M., Radford, J. A., Salles, G., Sonneveld, P., ... Alliance, A. (2014). Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification. Journal of Clinical Oncology, 32(27), 3059–3068. https://doi.org/10.1200/JCO.2013.54.8800
6. O'Malley, D. P., Dogan, A., Fedoriw, Y., Fend, F., Goodlad, J. R., Inghirami, G., Jaffe, E. S., Karner, K. M., Kinney, M. C., Milligan, L., Morrissette, J. J. D., Orazi, A., Pileri, S. A., Pittaluga, S., Ribeiro-Silva, A., Swerdlow, S. H., & American Registry of Pathology. (2019). American registry of pathology expert opinions: Immunohistochemical evaluation of classic Hodgkin lymphoma. Annals of Diagnostic Pathology, 39, 105–110. https://doi.org/10.1016/j.anndiagpath.2019.02.012
7. Radhakrishnan, V. S., Longley, J., & Johnson, P. W. M. (2024). Antibody based therapies in Hodgkin lymphoma. Cancer Treatment Reviews, 122, Article 102647. https://doi.org/10.1016/j.ctrv.2023.102647
8. Singh, D., Vaccarella, S., Gini, A., de Martel, C., Chan, J. K. C., Bray, F., & Miranda-Filho, A. (2022). Global patterns of Hodgkin lymphoma incidence and mortality in 2020 and a prediction of the future burden in 2040. International Journal of Cancer, 150(19), 1941–1947. https://doi.org/10.1002/ijc.33948
9. GBD 2019 Asia and All Cancers Collaborators. (2024). Temporal patterns of cancer burden in Asia, 1990-2019: A systematic examination for the Global Burden of Disease 2019 study. The Lancet Regional Health - Southeast Asia, 21, Article 100333. https://doi.org/10.1016/j.lansea.2023.100333
10. Ferlay, J., Ervik, M., Lam, F., Colombet, M., Mery, L., Piñeros, M., Znaor, A., Soerjomataram, I., & Bray, F. (2024). Global Cancer Observatory: Cancer Today (version 1.1). International Agency for Research on Cancer.
11. Aoki, R., Karube, K., Sugita, Y., Nomura, Y., Shimizu, K., Kimura, Y., Hashikawa, K., Zurasa, M., & Ohshima, K. (2008). Distribution of malignant lymphoma in Japan: Analysis of 2260 cases, 2001–2006. Pathology International, 58(3), 174–182. https://doi.org/10.1111/j.1440-1827.2007.02207.x
12. Jung, K. W., Park, S., Kong, H. J., Won, Y. J., Boo, Y. K., Shin, H. R., Park, E. C., & Lee, J. S. (2010). Cancer statistics in Korea: Incidence, mortality and survival in 2006–2007. Journal of Korean Medical Science, 25(8), 1113–1121. https://doi.org/10.3346/jkms.2010.25.8.1113
13. Azizah, A. M., Hashimah, B., Nirmal, K., Azlina, A. A., & Zubaidah, Z. A. (2019). Malaysia National Cancer Registry Report 2012–2016. National Cancer Institute, Ministry of Health Malaysia.
14. Sukpanichnant, S. (2004). Analysis of 1983 cases of malignant lymphoma in Thailand according to the World Health Organization classification. Human Pathology, 35(2), 224–230. https://doi.org/10.1016/j.humpath.2003.09.004
15. Sukpanichnant, S., Sonakul, D., Piankijagum, A., Wanachiwanawin, W., Veerakul, G., Intragumtornchai, T., & Jinawath, A. (1998). Malignant lymphoma in Thailand: Changes in the frequency of malignant lymphoma determined from a histopathologic and immunophenotypic analysis of 425 cases at Siriraj Hospital. Cancer, 83(6), 1197–1204. https://doi.org/10.1002/(SICI)1097-0142(19980915)83:6<1197::AID-CNCR20>3.0.CO;2-H
16. Wu, S. J., Chen, C. Y., Su, I. J., Tien, H. F., Wang, C. H., Huang, S. Y., Chou, W. C., Yao, M., Lin, D. T., Tang, J. L., & Cheng, A. L. (2008). Clinical characteristics and treatment response of Hodgkin's lymphoma in Taiwan. Journal of the Formosan Medical Association, 107(1), 4–12. https://doi.org/10.1016/S0929-6646(08)60002-X
17. Liu, W., Song, Y., Zhu, J., & National Health Commission Corporate Database Group. (2023). Introduction of lymphoma database of National Health Commission of the People's Republic of China. Hematological Oncology, 41(S1), 113. https://doi.org/10.1002/hon.3163_78
18. Liu, W. P., Liu, J., Song, Y., Wang, X. H., Zhou, D. B., & Zhu, J. (2022). Burden of lymphoma in China, 1990–2019: An analysis of the global burden of diseases, injuries, and risk factors study 2019. Aging (Albany NY), 14(7), 3175–3190. https://doi.org/10.18632/aging.204007
19. Altekruse, S. F., Kosary, C. L., Krapcho, M., Neyman, N., Aminou, R., Waldron, W., Ruhl, J., Howlader, N., Tatalovich, Z., Cho, H., Mariotto, A., Eisner, M. P., Lewis, D. R., Cronin, K., & Edwards, B. K. (Eds.). (2010). SEER Cancer Statistics Review, 1975–2007. National Cancer Institute. https://seer.cancer.gov/archive/csr/1975_2007/
20. Huang, J., Pang, W. S., Lok, V., Zhang, L., Lin, X., Lucero-Prisno, D. E., III, Xu, W., Zheng, Z. J., Elcarte, E., Withers, M., & Wong, M. C. S. (2022). Incidence, mortality, risk factors, and trends for Hodgkin lymphoma: A global data analysis. Journal of Hematology & Oncology, 15, Article 57. https://doi.org/10.1186/s13045-022-01281-9
21. Won, Y. W., Kwon, J. H., Lee, S. I., Oh, S. Y., Kim, K. S., Kim, S. J., Kim, W. S., Mun, Y. C., & Consortium for Improving Survival of Lymphoma (CISL). (2012). Clinical features and outcomes of Hodgkin's lymphoma in Korea: Consortium for Improving Survival of Lymphoma (CISL). Annals of Hematology, 91(2), 223–233. https://doi.org/10.1007/s00277-011-1279-0
22. Zhu, Y. J., Sun, Y. L., Xia, Y., Jiang, W. Q., & Lu, Y. (2012). Clinical characteristics and prognostic factors in Chinese patients with Hodgkin's lymphoma. Medical Oncology, 29(2), 1127–1133. https://doi.org/10.1007/s12032-011-9952-4
23. Asano, N., Oshiro, A., Matsuo, K., Kagami, Y., Ishida, F., Suzuki, R., Kinoshita, T., Shimoyama, Y., Tamaru, J., Yoshino, T., Nakamura, S., & Ohshima, K. (2006). Prognostic significance of T-cell or cytotoxic molecules phenotype in classical Hodgkin's lymphoma: A clinicopathologic study. Journal of Clinical Oncology, 24(28), 4626–4633. https://doi.org/10.1200/JCO.2006.06.7454
24. Schaapveld, M., Aleman, B. M., van Eggermond, A. M., Janus, C. P. M., Krol, A. D. G., van der Maazen, R. W. M., Roesink, J., Louwman, M. W. J., de Boer, J. P., van den Belt-Dusebout, A. W., De Bruin, M. L., Hauptmann, M., & van Leeuwen, F. E. (2015). Second cancer risk up to 40 years after treatment for Hodgkin's lymphoma. New England Journal of Medicine, 373(26), 2499–2511. https://doi.org/10.1056/NEJMoa1505949
25. Behringer, K., Mueller, H., Goergen, H., Thielen, I., Behrens, S. K., Rasche, F. M., Kanz, L., Fischer, R., Pluetschow, A., Fuchs, M., Engert, A., & Borchmann, P. (2013). Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. Journal of Clinical Oncology, 31(2), 231–239. https://doi.org/10.1200/JCO.2012.42.5272
26. Harel, S., Ferme, C., & Poirot, C. (2011). Management of fertility in patients treated for Hodgkin's lymphoma. Haematologica, 96(11), 1692–1699. https://doi.org/10.3324/haematol.2011.040600
27. Bjerring, A. W., Smeland, K. H., Stokke, T., Kiserud, C. E., Holte, H., Kjekshus, J., & Edvardsen, T. (2024). Long-term cardiac effects of modern treatment for Hodgkin's lymphoma. Cardio-Oncology, 10, Article 19. https://doi.org/10.1186/s40959-024-00216-9
28. Martin, W. G., Ristow, K. M., Habermann, T. M., Colgan, J. P., Witzig, T. E., & Ansell, S. M. (2005). Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. Journal of Clinical Oncology, 23(30), 7614–7620. https://doi.org/10.1200/JCO.2005.02.7318
29. Skoetz, N., Will, A., Monsef, I., Brillant, C., Engert, A., & Borchmann, P. (2017). Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma. Cochrane Database of Systematic Reviews, 2017(5), CD007941. https://doi.org/10.1002/14651858.CD007941.pub3
30. Engert, A., Haverkamp, H., Kobe, C., Markova, J., Renner, C., Ho, A., Zijlstra, J., Král, Z., Fuchs, M., Hallek, M., Eich, H. T., Müller, R. P., Stein, H., Karimi, M., Ortholan, C., Milanovic, N., Santoro, A., Schneider, G., Wilhelm, M., ... Borchmann, P. (2012). Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): A randomised, open-label, phase 3 non-inferiority trial. The Lancet, 379(9828), 1791–1799. https://doi.org/10.1016/S0140-6736(11)61940-5
31. Ansell, S. M., Radford, J., Connors, J. M., Dlugosz-Danecka, M., Kim, W. S., Gallamini, A., Ramchandren, R., Friedberg, J. W., Advani, R., Hutchings, M., Evens, A. M., Sasse, S., Velasquez, W. S., Zinzani, P. L., Zhang, B., Shen, R., Kalisch, V., Joseph, M., Fanale, M., ... Straus, D. J. (2022). Overall survival with brentuximab vedotin in stage III or IV Hodgkin's lymphoma. New England Journal of Medicine, 387(4), 310–320. https://doi.org/10.1056/NEJMoa2206125
32. Borchmann, P., Ferdinandus, J., Schneider, G., Greil, R., Moosmann, P., Eichenauer, D. A., Sasse, S., Topp, M. S., Soekler, M., Hitz, F., van der Maazen, R. W. M., Dierickx, D., Zijlstra, J. M., Clausen, M. R., Bittenbring, J., Hüttmann, A., Zenz, T., Witzens-Harig, M., Meissner, J., ... Fuchs, M. (2024). Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): A randomised, multicentre, parallel, open-label, phase 3 trial. The Lancet, 404(10450), 341–352. https://doi.org/10.1016/S0140-6736(24)01021-5
33. Herrera, A. F., LeBlanc, M., Castellino, S. M., Li, H., Jaeger, E. D., Evans, A. G., Parsons, S. K., Rutherford, S. C., Advani, R. H., Evens, A. M., Caimi, P. F., Thomas, S. A., Little, R. F., Smith, S. M., Kelly, K. M., Karaesmen, E., Kothari, S. J., Constine, L. S., Shah, B. D., ... Friedberg, J. W. (2024). Nivolumab+AVD in advanced-stage classic Hodgkin's lymphoma. New England Journal of Medicine, 391(15), 1379–1389. https://doi.org/10.1056/NEJMoa2400585
34. Duggan, D. B., Petroni, G. R., Johnson, J. L., Glick, J. H., Fisher, R. I., Connors, J. M., Canellos, G. P., & Peterson, B. A. (2003). Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: Report of an intergroup trial. Journal of Clinical Oncology, 21(4), 607–614. https://doi.org/10.1200/JCO.2003.04.084
35. Santoro, A., Bonadonna, G., Valagussa, P., Zucali, R., Viviani, S., Villani, F., Pagnoni, A. M., Bonfante, V., & Monfardini, S. (1987). Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: Superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. Journal of Clinical Oncology, 5(1), 27–37. https://doi.org/10.1200/JCO.1987.5.1.27
36. Ogura, M., Itoh, K., Kinoshita, T., Ohnishi, K., Kaba, H., Shimada, T., Chou, T., Maruyama, F., Morishima, Y., Hotta, T., & Tobinai, K. (2010). Phase II study of ABVd therapy for newly diagnosed clinical stage II-IV Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG 9305). International Journal of Hematology, 92(5), 713–724. https://doi.org/10.1007/s12185-010-0720-3
37. Tan, G. F., Goh, S., Chang, E. W. Y., Cheong, M. A., Liew, P. Y., & Bee, P. C. (2023). Post-treatment neutrophil and lymphocyte counts predict progression-free survival following first-line chemotherapy in Hodgkin's lymphoma. Hematology Reports, 15(1), 108–118. https://doi.org/10.3390/hematolrep15010012
38. Mondello, P., Musolino, C., Dogliotti, I., Vaxman, I., Ferrero, S., Ferreri, A. J. M., Gini, G., Caracciolo, F., Zaja, F., Botto, B., Cavallo, F., Marcheselli, L., & Witzig, T. E. (2020). ABVD vs BEACOPP escalated in advanced-stage Hodgkin's lymphoma: Results from a multicenter European study. American Journal of Hematology, 95(9), 1030–1037. https://doi.org/10.1002/ajh.25870
39. Suwanban, T., Chamnanchanunt, S., Thungthong, P., Rujirojindakul, P., Nawarawong, W., & Rojnuckarin, P. (2023). Survival rates of adult patients with Hodgkin lymphoma who underwent ABVD versus escalated BEACOPP in a resource-limited country: An observational study. Cancer Reports, 6(7), e1839. https://doi.org/10.1002/cnr2.1839
40. Borchmann, S., Engert, A., & Boll, B. (2018). Hodgkin lymphoma in elderly patients. Current Opinion in Oncology, 30(5), 308–316. https://doi.org/10.1097/CCO.0000000000000473
41. Evens, A. M., Hong, F., Gordon, L. I., Fisher, R. I., Bartlett, N. L., Connors, J. M., Gascoyne, R. D., Wagner, H., Jr., Hochster, H. S., & Horning, S. J. (2013). The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: A comprehensive analysis from the North American intergroup trial E2496. British Journal of Haematology, 161(1), 76–86. https://doi.org/10.1111/bjh.12224
42. Connors, J. M., Jurczak, W., Straus, D. J., Ansell, S. M., Kim, W. S., Gallamini, A., Younes, A., Alekseev, S., Illés, Á., Picardi, M., Lech-Maranda, E., Oki, Y., Feldman, T., Sasse, S., Zinzani, P. L., Ramchandren, R., Poddubnaya, I., Minuk, L., Naldi, A., ... Fanale, M. A. (2018). Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma. New England Journal of Medicine, 378(4), 331–344. https://doi.org/10.1056/NEJMoa1708984
43. Longo, D. L., & Armitage, J. O. (2022). A better treatment for advanced-stage Hodgkin's lymphoma? New England Journal of Medicine, 387(4), 370–372. https://doi.org/10.1056/NEJMe2207137
44. Evens, A. M., Connors, J. M., Younes, A., Ansell, S. M., Straus, D. J., Radford, J., Dlugosz-Danecka, M., Kim, W. S., Gallamini, A., Ramchandren, R., Friedberg, J. W., Hutchings, M., Sasse, S., Velasquez, W. S., Zinzani, P. L., Kalisch, V., Joseph, M., Fanale, M. A., & Liu, R. (2022). Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: A detailed analysis from the phase III ECHELON-1 study. Haematologica, 107(5), 1086–1094. https://doi.org/10.3324/haematol.2021.040170
45. Lynch, R. C., Alig, S. K., Ujjani, C. S., Smith, S. D., Shadman, M., Palanca-Wessels, M. C. A., Gowan, M., Mylan, J. E., Warren, E. H., Voutsinas, J., Wu, Q., Gopal, A. K., & Fromm, J. R. (2023). Durable remissions in advanced stage and molecularly high risk untreated classic Hodgkin lymphoma with pembrolizumab + AVD. Blood, 142(Suppl 1), 4429. https://doi.org/10.1182/blood-2023-181514
46. Gallamini, A., Rossi, A., Patti, C., Picardi, M., Romano, A., Cantonetti, M., Gini, G., D'Alò, F., Tarella, C., Zaja, F., Tucci, A., Nassi, L., Salvi, F., Corradini, P., Trentin, L., Liberati, A. M., Cox, M. C., Marcheselli, L., Biggi, A., & Federico, M. (2020). Consolidation radiotherapy could be safely omitted in advanced Hodgkin lymphoma with large nodal mass in complete metabolic response after ABVD: Final analysis of the randomized GITIL/FIL HD0607 trial. Journal of Clinical Oncology, 38(33), 3905–3913. https://doi.org/10.1200/JCO.20.00935
47. Johnson, P., Federico, M., Kirkwood, A., Fosså, A., Berkahn, L., Carella, A., D'Amore, F., Enjeti, A. K., Franceschetto, A., Fulham, M., Levin, M. D., McDonagh, J., Rossi, A., Smith, P., Stevens, L., Turner, G., Pagani, L., Anderson, J. J., Barrington, S. F., & Radford, J. (2016). Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma. New England Journal of Medicine, 374(25), 2419–2429. https://doi.org/10.1056/NEJMoa1510093
48. Luminari, S., Fossa, A., Trotman, J., Berkahn, L., Levin, M. D., D'Amore, F., Enjeti, A. K., Kirkwood, A., Smith, P., Stevens, L., Pagani, L., Anderson, J. J., Barrington, S. F., Radford, J., & Johnson, P. (2024). Long-term follow-up of the response-adjusted therapy for advanced Hodgkin lymphoma trial. Journal of Clinical Oncology, 42(1), 13–18. https://doi.org/10.1200/JCO.23.01041
49. Kusumoto, S., Munakata, W., Machida, R., Ogura, M., Kinoshita, T., Shimada, T., Chou, T., Maruyama, F., Morishima, Y., Hotta, T., & Tobinai, K. (2024). Interim PET-guided ABVD or ABVD/escalated BEACOPP for newly diagnosed advanced-stage classic Hodgkin lymphoma (JCOG1305). Cancer Science, 115(10), 3384–3393. https://doi.org/10.1111/cas.16279
50. Borchmann, P., Goergen, H., Kobe, C., Lohri, A., Greil, R., Zijlstra, J. M., Markova, J., Meissner, J., Feuring-Buske, M., Hüttmann, A., Dierickx, D., Fuchs, M., Stein, H., SanMiguel, M., Eich, H. T., Baues, C., Almrádi, A., Dietlein, M., Hasenclever, D., ... Engert, A. (2017). PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): Final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. The Lancet, 390(10114), 2790–2802. https://doi.org/10.1016/S0140-6736(17)32134-7
51. Casasnovas, R. O., Bouabdallah, R., Brice, P., Brink, M., Westin, E., & AHL2011 Investigators. (2019). PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): A randomised, multicentre, non-inferiority, phase 3 study. The Lancet Oncology, 20(2), 202–215. https://doi.org/10.1016/S1470-2045(18)30738-5
52. Gallamini, A., Tarella, C., Viviani, S., Rossi, A., Patti, C., Picardi, M., Romano, A., Cantonetti, M., Gini, G., D'Alò, F., Zaja, F., Tucci, A., Nassi, L., Salvi, F., Corradini, P., Trentin, L., Liberati, A. M., Cox, M. C., Marcheselli, L., ... Federico, M. (2018). Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography/computed tomography scan after two ABVD cycles: Long-term results of the GITIL/FIL HD 0607 trial. Journal of Clinical Oncology, 36(5), 454–462. https://doi.org/10.1200/JCO.2017.75.2543
53. Yahya, N., Sukiman, N. K., Suhaimi, N. A., & Azlina, N. A. (2019). How many roads must a Malaysian walk down? Mapping the accessibility of radiotherapy facilities in Malaysia. PLoS One, 14(3), e0213583. https://doi.org/10.1371/journal.pone.0213583
54. Peiris, G. S., Pawiro, S. A., Kasim, M. F., & Soejoko, D. S. (2023). Failure modes and downtime of radiotherapy LINACs and multileaf collimators in Indonesia. Journal of Applied Clinical Medical Physics, 24(8), e13756. https://doi.org/10.1002/acm2.13756
55. Jacomina, L. E., Agas, R. A. F., Benedicto, M., & Calaguas, R. B. (2024). Radiation oncology training in the Philippines: Bridging gaps for improved cancer care in low- and middle-income countries. JCO Global Oncology, 10, Article e2300462. https://doi.org/10.1200/GO.23.00462
56. Flores, J. A. S., Lo, C. C. C., Tomagan, J. M. P., & Dee, E. C. (2024). Radiotherapy services in the Philippines: Exploring geographical barriers to improve access to care. The Lancet Regional Health - Western Pacific, 51, Article 101219. https://doi.org/10.1016/j.lanwpc.2024.101219
57. Younes, A., Gopal, A. K., Smith, S. E., Ansell, S. M., Rosenblatt, J. D., Savage, K. J., Ramchandren, R., Bartlett, N. L., Cheson, B. D., de Vos, S., Forero-Torres, A., Moskowitz, C. H., Connors, J. M., Engert, A., Larsen, E. K., Kennedy, D. A., & Sievers, E. L. (2012). Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. Journal of Clinical Oncology, 30(18), 2183–2189. https://doi.org/10.1200/JCO.2011.38.0410
58. Moskowitz, C. H., Nademanee, A., Masszi, T., Agura, E., Holte, H., Stevens, D. A., Borchmann, P., Bryce, R., Radford, J., & AETHERA Study Group. (2015). Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): A randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 385(9980), 1853–1862. https://doi.org/10.1016/S0140-6736(15)60165-9
59. Chen, R., Zinzani, P. L., Fanale, M. A., Armand, P., Johnson, N. A., Brice, P., Radford, J., Ribrag, V., Molin, D., Vassilakopoulos, T. P., Tomita, A., von Tresckow, B., Shipp, M. A., Zhang, J., Ricart, A. D., Balakumaran, A., & Moskowitz, C. H. (2017). Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. Journal of Clinical Oncology, 35(19), 2125–2132. https://doi.org/10.1200/JCO.2016.72.1316
60. Younes, A., Santoro, A., Shipp, M., Zinzani, P. L., Timmerman, J. M., Ansell, S., Armand, P., Fanale, M., Ratanatharathorn, V., Kuruvilla, J., Cohen, J. B., Collins, G. P., Savage, K. J., Trneny, M., Kato, K., Farsaci, B., Parker, S. M., Vassilakopoulos, T. P., ... CheckMate 205 Investigators. (2016). Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: A multicentre, multicohort, single-arm phase 2 trial. The Lancet Oncology, 17(9), 1283–1294. https://doi.org/10.1016/S1470-2045(16)30167-X
61. Chen, R., Gopal, A. K., Smith, S. E., Ansell, S. M., Rosenblatt, J. D., Savage, K. J., Ramchandren, R., Bartlett, N. L., Cheson, B. D., de Vos, S., Forero-Torres, A., Moskowitz, C. H., Connors, J. M., Engert, A., Larsen, E. K., Kennedy, D. A., & Sievers, E. L. (2016). Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood, 128(12), 1562–1566. https://doi.org/10.1182/blood-2016-02-699850
62. Ansell, S. M., Brockelmann, P. J., von Keudell, G., Armand, P., Zinzani, P. L., Timmerman, J. M., Cohen, J. B., Savage, K. J., Engert, A., Shipp, M. A., Kato, K., Ligon, A. H., Carey, C. D., Tan, X., Farsaci, B., Sumbul, A., & Fanale, M. A. (2023). Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study. Blood Advances, 7(20), 6266–6274. https://doi.org/10.1182/bloodadvances.2023010508
63. Armand, P., Zinzani, P. L., Lee, H. J., Johnson, N. A., Brice, P., Radford, J., Ribrag, V., Molin, D., Vassilakopoulos, T. P., Tomita, A., von Tresckow, B., Shipp, M. A., Gause, C. K., Yu, J., Marinello, P., & Chen, R. (2023). Five-year follow-up of KEYNOTE-087: Pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma. Blood, 142(10), 878–886. https://doi.org/10.1182/blood.2023020268
64. Izutsu, K., Ogura, M., Tobinai, K., Ando, K., Choi, I., Utsumi, T., Maruyama, D., & Yamamoto, K. (2021). Safety profile of brentuximab vedotin in Japanese patients with relapsed/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: A post-marketing surveillance study. International Journal of Hematology, 113(3), 404–412. https://doi.org/10.1007/s12185-020-03038-0
65. Maruyama, D., Terui, Y., Yamamoto, K., Hatake, K., Tobinai, K., Ando, K., Choi, I., Utsumi, T., & Izutsu, K. (2020). Final results of a phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma. Japanese Journal of Clinical Oncology, 50(11), 1265–1273. https://doi.org/10.1093/jjco/hyaa114
66. Hasenclever, D., & Diehl, V. (1998). A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. New England Journal of Medicine, 339(21), 1506–1514. https://doi.org/10.1056/NEJM199811193392106
67. Moccia, A. A., Donaldson, J., Chhanabhai, M., Hoskins, P., Klasa, R. J., Savage, K. J., Shenkier, T. N., Gascoyne, R. D., Connors, J. M., & Sehn, L. H. (2012). International Prognostic Score in advanced-stage Hodgkin's lymphoma: Altered utility in the modern era. Journal of Clinical Oncology, 30(27), 3383–3388. https://doi.org/10.1200/JCO.2012.42.0935
68. Relecom, A., Federico, M., Connors, J. M., & Guidelines Group. (2020). Resources-stratified guidelines for classical Hodgkin lymphoma. International Journal of Environmental Research and Public Health, 17(5), 1783. https://doi.org/10.3390/ijerph17051783
69. Das, M. (2023). Indonesia launches three programmes to boost cancer care. The Lancet Oncology, 24(2), 131. https://doi.org/10.1016/S1470-2045(23)00028-2
70. Eala, M. A. B., Maslog, E. A. S., Dee, E. C., & Calaguas, R. B. (2022). Geographic distribution of cancer care providers in the Philippines. JCO Global Oncology, 8, Article e2200138. https://doi.org/10.1200/GO.22.00138
71. Tan, S. C., Poh, W. T., Yong, A. C. H., Low, T. Y., & MACR Scientific Committee. (2023). Challenges and strategies for improving access to cancer drugs in Malaysia: Summary of opinions expressed at the 2nd MACR International Scientific Conference 2022. Cancer Management and Research, 15, 851–862. https://doi.org/10.2147/CMAR.S414512
72. Feliciano, E. J. G., Ho, F. D. V., Yee, K., & Southeast Asia Cancer Care Collaborative. (2023). Cancer disparities in Southeast Asia: Intersectionality and a call to action. The Lancet Regional Health - Western Pacific, 41, Article 100971. https://doi.org/10.1016/j.lanwpc.2023.100971
73. Kumar, A., Burger, I. A., Zhang, Z., Schöder, H., & Moskowitz, C. H. (2016). Definition of bulky disease in early stage Hodgkin lymphoma in computed tomography era: Prognostic significance of measurements in the coronal and transverse planes. Haematologica, 101(10), 1237–1243. https://doi.org/10.3324/haematol.2016.146522
74. Onizuka, M., Kojima, M., Matsui, K., Machida, S., & Ando, K. (2017). Successful treatment with low-dose nivolumab in refractory Hodgkin lymphoma after allogeneic stem cell transplantation. International Journal of Hematology, 106(1), 141–145. https://doi.org/10.1007/s12185-017-2208-8
75. Hwang, Y. Y., Khong, P. L., & Kwong, Y. L. (2017). Low-dose nivolumab induced remission in refractory classical Hodgkin lymphoma. Annals of Hematology, 96(7), 1219–1220. https://doi.org/10.1007/s00277-017-3004-8
76. Chan, T. S. Y., Hwang, Y. Y., Khong, P. L., & Kwong, Y. L. (2020). Low-dose pembrolizumab and nivolumab were efficacious and safe in relapsed and refractory classical Hodgkin lymphoma: Experience in a resource-constrained setting. Hematological Oncology, 38(5), 726–736. https://doi.org/10.1002/hon.2801
77. Lepik, K. V., Fedorova, L. V., Kondakova, E. V., Mikhailova, N. B., & Afanasyev, B. V. (2020). A phase 2 study of nivolumab using a fixed dose of 40 mg (nivo40) in patients with relapsed/refractory Hodgkin lymphoma. HemaSphere, 4(5), e480. https://doi.org/10.1097/HS9.0000000000000480
78. Chan, T. S., Luk, T. H., Lau, J. S., & Kwong, Y. L. (2017). Low-dose pembrolizumab for relapsed/refractory Hodgkin lymphoma: High efficacy with minimal toxicity. Annals of Hematology, 96(4), 647–651. https://doi.org/10.1007/s00277-017-2936-3
79. Kwong, Y. L., Lopes, D., & Khong, P. L. (2017). Low-dose pembrolizumab induced remission in patients with refractory classical Hodgkin lymphoma. British Journal of Haematology, 176(1), 131–132. https://doi.org/10.1111/bjh.14376
80. Kwong, Y. L., Loong, F., & Khong, P. L. (2019). Low-dose pembrolizumab re-treatment induced complete radiologic and molecular remission in Hodgkin lymphoma recurring from a previous relapse successfully treated by pembrolizumab. Annals of Hematology, 98(10), 2451–2455. https://doi.org/10.1007/s00277-019-03756-x
81. Sim, J. P. Y., Au-Yeung, R., & Kwong, Y. L. (2020). Low-dose pembrolizumab induced complete radiologic and molecular response of posttransplant lymphoproliferative disorder presenting as classical Hodgkin lymphoma. Annals of Hematology, 99(2), 385–388. https://doi.org/10.1007/s00277-019-03884-4
82. Othman, M. Y., Blair, S., Nah, S. A., & Pediatric Oncology Collaborative. (2020). Pediatric solid tumor care and multidisciplinary tumor boards in low- and middle-income countries in Southeast Asia. JCO Global Oncology, 6, Article e2000284. https://doi.org/10.1200/GO.20.00284
83. Kim, S. J., Yoon, D. H., Jaccard, A., Chng, W. J., Lim, S. T., Hong, H., Park, Y., Ko, Y. H., & Kwong, Y. L. (2016). A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: A multicentre, retrospective analysis. The Lancet Oncology, 17(3), 389–400. https://doi.org/10.1016/S1470-2045(15)00533-1
84. Cho, H., Yoon, D. H., Chan, J. Y., & Asia-Pacific Lymphoma Registry Group. (2023). Treatment patterns in patients with mantle cell lymphoma: Updated report of the Asia-Pacific multinational retrospective registry study. Blood, 142(Suppl 1), 6638–6640. https://doi.org/10.1182/blood-2023-182390
85. Agrawal, S., Feng, Y., Roy, A., Kollia, G., & Marathe, P. (2016). Nivolumab dose selection: Challenges, opportunities, and lessons learned for cancer immunotherapy. Journal for ImmunoTherapy of Cancer, 4, Article 72. https://doi.org/10.1186/s40425-016-0177-2
86. Gandhi, K. A., Shirsat, A., Hj, S. K., & Patil, V. (2024). Pharmacokinetics and clinical outcomes of low-dose nivolumab relative to conventional dose in patients with advanced cancer. Cancer Chemotherapy and Pharmacology, 94(4), 659–668. https://doi.org/10.1007/s00280-024-04683-1
87. Eniu, A., Cherny, N. I., Bertram, M., & Global Oncology Committee. (2019). Cancer medicines in Asia and Asia-Pacific: What is available, and is it effective enough? ESMO Open, 4(2), e000483. https://doi.org/10.1136/esmoopen-2018-000483
88. Tan, Y. H., Yoon, D. H., Davies, A. J., & Asia-Pacific CAR T-Cell Collaborative. (2025). Improving access to chimeric antigen receptor T-cells for refractory or relapsing diffuse large B cell lymphoma therapy in Asia. Discovery Oncology, 16, Article 181. https://doi.org/10.1007/s12672-025-01290-x
89. Barrios, C., de Lima Lopes, G., Yusof, M. M., & Global Access to Oncology Drugs Consortium. (2023). Barriers in access to oncology drugs—A global crisis. Nature Reviews Clinical Oncology, 20(1), 7–15. https://doi.org/10.1038/s41571-022-00700-8
90. Lee, K. S., Ming, L. C., Lean, Q. Y., & ASEAN Health Policy Research Group. (2019). Cross-border collaboration to improve access to medicine: Association of Southeast Asian Nations perspective. Journal of Epidemiology and Global Health, 9(2), 93–97. https://doi.org/10.2991/jegh.k.190408.001